1. Scrip
  2. >>Business

Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads

 
• By Anju Ghangurde

Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary

Stacked Bricks
Takeda Continues Measured Step Up In India • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. continues to build its rare diseases portfolio brick by brick in India drawing on the ex-Shire PLC range of therapies, the latest introduction being Adynovate [antihemophilic factor (recombinant), PEGylated] for hemophilia A patients.

Takeda’s $62bn purchase of Shire had earlier brought with it a range of on-market products in India, largely in the hematology segment including Advate , Recombinate, FEIBA, Hemofil M, Immunate, Rixubis and Immunine and Adynovate is now expected to build on that portfolio strength

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.